Activists file post grant opposition to challenge a patent prevents purchase of cheaper treatment for hepatitis C
In GTPI’s opinion, this concession is undeserved. The main argument is that the patent
lacks sufficiency disclosure, ie, it does not have the level of detail necessary for the
technology described therein to be reproduced by a person skilled in the art. This is
fundamental to justify the granting of the patent.
Protests in Brazil exposures Gilead’s greed to block generic sofosbuvir
In Rio de Janeiro activists demand INPI to reject the patent. In São Paulo, activists remembered the deaths due to lack of access in front of Gilead’s office.
Read moreGilead’s patent application on sofosbuvir rejected in Brazil
The Working Group on Intellectual Property of the Brazilian Network for Integration of Peoples (GTPI/Rebrip), a coalition of civil society organizations and activists coordinated by the Brazilian Interdisciplinary Aids Association (ABIA), filed several patent oppositions in this case.
Read more